CTLA4 and neoplasm: Since the combination of DSP-0509 and anti-PD-1 antibody enhanced anti-tumor activity, we next evaluated the anti-tumor activity of the combination with anti-CTLA-4 antibody, a different immune-checkpoint blocker from the anti-PD-1 antibody used clinically.